Showing 15 posts of 150 posts found.

Jardiance scores more cardiovascular outcomes data

November 10, 2015
Manufacturing and Production Boehringer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Victoza, cardiovascular outcomes, diabetes, empagliflozin, jardiance, lilly, liraglutide, type 2 diabetes

A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug …


Lilly and Boehringer launch biosimilar insulin in the UK

August 26, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Boehringer, Boehringer Ingelheim, Eli Lilly, Lantus, abasaglar, basal insulin, biosimilar, biosimilars, diabetes, insuling glargine, lilly

Lilly and Boehringer Ingelheim have launched their biosimilar insulin, called abasaglar, for the UK market. Abasaglar will now challenge the …

Boehringer and Vitae Pharma drug fails in mid-stage trial

July 1, 2015
Research and Development BI, Boehringer, Boehringer Ingelheim, Vitae Pharmaceuticals, diabetes, type 2 diabetes

A pipeline diabetes drug co-developed by Vitae Pharma and German giants Boehringer Ingelheim has failed to show benefits in a …

Boehringer image

Boehringer scores trial success for Pradaxa antidote

June 29, 2015
Research and Development, Sales and Marketing Boehringer, Pradaxa, idarucizumab

Bosses at Boehringer Ingelheim say the latest results of a study of idarucizumab, and antidote for its blockbuster blood-thinner Pradaxa, …

Boehringer and Eureka reach cancer antibodies deal

May 22, 2015
Research and Development, Sales and Marketing Boehringer, eureka

Boehringer Ingelheim and Eureka Therapeutics have entered into a research agreement for the discovery of novel therapeutic antibodies in oncology.No …

FDA image

FDA issues more diabetes drug warnings

May 18, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Boehringer, J&J, JJ, lilly

The FDA has warned that a class of type 2 diabetes drugs manufactured by several big pharma firms could cause …

Boehringer widens IPF drug’s reach

May 18, 2015
Sales and Marketing Boehringer, Esbriet, ats, brett wells, nintedanib, ofev

Boehringer Ingelheim has highlighted new data for its idiopathic pulmonary fibrosis (IPF) treatment Ofev in a Phase II study on …

Boehringer assures future growth following sales drop

April 23, 2015
Sales and Marketing Boehringer, COPD, Glyxambi, Striverdi Respimat, empagliflozin, empagliflozin/linagliptin, financials, full year, jardiance, nintedanib, ofev, olodaterol, results

Boehringer says it is positioned for future growth in the wake of filing a decline in profit for 2014 and …

Sanofi image

Sanofi rules out Toujeo discount in diabetes

April 14, 2015
Sales and Marketing 100 U/mL, Boehringer, Lantus, insulin glargine [rDNA origin] injection, lilly, toujeo

Sanofi has revealed that it will not discount its new insulin Toujeo more than its current blockbuster Lantus, despite lacking …

EMA image

EMA committee recommends five drugs for approval

March 30, 2015
Sales and Marketing Boehringer, CHMP, EMA, Eisai, Europe, Gardasil, Lenvima, Merck, akynzio, jardiance, lilly

Cancer and diabetes treatments are among those given the go ahead in the latest round of approvals by the EMA. …

NICE image

NICE decisions made on Bayer, Celgene and Boehringer drugs

March 26, 2015
Sales and Marketing Bayer, Boehringer, Celgene, NHS, Xarelto, imnovid, jardiance

In final guidance NICE has recommended Bayer’s Xarelto and Boehringer’s Jardiance for NHS funding, but not Celgene’s Imnovid. Bayer’s Xarelto …

Lilly and Boehringer diabetes drug sees US launch

March 24, 2015
Sales and Marketing Boehringer, Glyxambi, Tradjenta, diabetes, empagliflozin/linagliptin, lilly, linagliptin

Lilly and Boehringer Ingelheim’s combo diabetes drug Glyxambi is now available to treat adult patients in the US. Glyxambi (empagliflozin/linagliptin) …

Ofev image

Boehringer eyes Ofev success in IPF and beyond

March 16, 2015
Sales and Marketing Boehringer, Esbriet, Roche, ingelheim, inpulsis, ipd, ofev

Experts say the launch of Boehringer Ingelheim’s new treatment for idiopathic pulmonary fibrosis (IPF) offers stiff competition to Roche’s Esbriet …

Boehringer image

Boehringer chases approval for anti-Pradaxa drug

March 3, 2015
Sales and Marketing Boehringer, Boehringer Ingelheim, Pradaxa, bleeding, dabigatran etexilate, idarucizumab

Boehringer Ingelheim is launching new drug applications for its investigational treatment to reverse the effects of its blood-thinning drug Pradaxa. …

Boehringer image

Boehringer’s beer breach at German congress

February 20, 2015
Medical Communications, Sales and Marketing ABPI, Boehringer, ERS, IPF, PMCPA, breach, code, munich

A complaint made by a pulmonologist against the competence of Boehringer Ingelheim speakers during a congress held in Germany last …

Latest content